After proxy battle Forest has questions to answer

Date August 17, 2012

Carl Icahn’s success in capturing one seat of the four he sought on the Forest Laboratories board was a rather limited victory for the activist investor. Executives had offered him a seat once before, so success in replacing the chairman of the compensation committee should not necessarily be seen as an endorsement of an outsider agenda.

However, the proxy battle that has stretched over two years has pointed up the essential challenge for the New York group: bouncing back from 2012’s second-steepest patent cliff and the share value doldrums that have accompanied its approach (As patent storm peaks Lilly and Astra have furthest to fall, February 9, 2012). Mr Icahn has said he does not believe Forest is an immediate acquisition target, but in touting success in pushing for trade sales of Amylin and Genzyme he made his message clear on what he sees as the long-term promise of the company. Furthermore, the central question of who will succeed 84-year-old chief executive Howard Solomon has yet to be answered.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd